PRISm – A COPD Risk factor and Smoking Cessation advocated by ICanCaRe

Introduction:

Preserved Ratio Impaired Spirometry (PRISm) is a critical indicator characterized by an FEV1 of <80% predicted and a FEV1/FVC ratio of >0.70. Identified as a precursor to Chronic Obstructive Pulmonary Disease (COPD), PRISm demands careful monitoring, particularly in individuals with respiratory symptoms. The studies by Mariko Kogo et al. and Daniel H Higbee et al. shed light on the significant correlation between PRISm, respiratory symptoms, and the heightened risk of developing COPD, emphasizing the urgency for effective tobacco cessation interventions. In this context, the ICanCaRe tobacco cessation intervention program emerges as a beacon of hope, advocating for smoking cessation on an individual basis. (www.icancare.in). This blog is in series with the previous blog on Increased risk of Asthma in Children exposed to secondhand smoke.( ICanCaRe Blog) (ICanCaRe LinkedIn)

Understanding the PRISm Challenge:

PRISm, when associated with respiratory symptoms such as cough, sputum, and dyspnea, poses an independent risk factor for COPD development, especially in individuals with a history of smoking. Even without symptoms at baseline, PRISm can progress within five years, leading to airflow limitations. In addition, individuals with PRISm could exhibit increased respiratory symptoms, poor health-related quality of life, multiple comorbidities, and increased mortality compared with those with normal spirometry. The quantitative assessment capability of PRISm becomes a crucial tool for identifying and addressing the risks faced by smokers, reinforcing the need for smoking cessation.

The ICanCaRe Tobacco Cessation Intervention program quantifies the need for individuals and the digital protocol puts the urgency for smoking cessation on an individual basis.

ICanCaRe: A Holistic Approach to Tobacco Cessation:

ICanCaRe tobacco cessation wellness program stands out as a comprehensive, evidence-based tobacco cessation program aligned with the latest research findings. Grounded in the insights from studies by Kogo et al. and Higbee et al., ICanCaRe adopts a holistic approach to empower individuals to overcome addiction, ensuring long-term abstinence, and reducing the risk of respiratory complications.

Key Components of ICanCaRe – ABCD of Tobacco Cessation:

1. ACTIVE MOTIVATION: ICanCaRe actively motivates tobacco users through quantitative and qualitative assessments, estimating the progressive risk associated with continued smoking.

2. BEHAVIOR INTERVENTION: Tailored behavioral counseling strategies address unique triggers contributing to tobacco addiction, crucial for addressing psychological aspects and enhancing successful cessation.

3. COMORBIDITY MANAGEMENT: Clinical assessments for associated morbidities are conducted, with specialists providing personalized care.

4. DRUGS and MEDICATIONS – Pharmacotherapy: The program integrates evidence-based pharmacotherapies to manage withdrawal symptoms and cravings, enhancing the effectiveness of the intervention and ensuring complete cessation.

Call 011-43077695 or write to info@icancare.in and download the ICanCaRe tobacco Wellness APP (http://app.icancare.in)

Conclusion – Empowering Individuals for a Tobacco-Free Future:

As we confront the challenges posed by PRISm and its link to respiratory symptoms, the ICanCaRe Tobacco Cessation Intervention program stands as a beacon of hope. By integrating the latest research findings into its framework, ICanCaRe not only recognizes the severity of the issue but actively addresses it through a personalized and holistic approach. It serves as a call to action for individuals to take charge of their respiratory health, break free from tobacco addiction, and embrace a future free from the shackles of compromised lung function.

ICanCaRe stands at the forefront of the battle against tobacco addiction, offering a lifeline to those grappling with the consequences of PRISm. Through its holistic approach, the program not only supports individuals in their journey to quit smoking but also contributes to a healthier, tobacco-free future for communities worldwide.

It is time we #savetheyouth. SAVE our next generation!! #knowtobacco to #notobacco

Reference:

1. Mariko Kogo et al. Longitudinal changes and association of respiratory symptoms with preserved ratio impaired spirometry (PRISm): The Nagahama Study. Ann Am Thorac Soc. 2023 Nov;20(11):1578-1586. doi: 10.1513/AnnalsATS.202301-050OC.

2. Daniel H Higbee et al. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis. Lancet Respir Med. 2022 Feb;10(2):149-157. doi: 10.1016/S2213-2600(21)00369-6.

Author –

1. Dr Shikha Jindal Consultant Pulmonologist Dr Shikha Jindal Gupta MD, CTCS(GU)

– Sr Consultant Pulmonologist,

– Certified Tobacco Cessation Specialist (Gujarat University by ICanCaRe)

Neo Super-Speciality Hospital, Noida

2. Dr Pawan Gupta M.Ch. Cancer Surgeon

 –  Sr. Director, Surgical Oncology

MAX Institute of Cancer Care, Vaishali, Patparganj and Noida

–          Founder Director – ICanCaRe – Innovative Cancer Care and Rehabilitation ICanCaRe, ICanCaRe Academy

–          Master Trainer – Tobacco Cessation Courses, Oral Cancers

#icancare #asthmaawareness #secondhandsmoke #icancareapp #pawangupta #icancareacademy #knowtobacco #Prism #COPD #smoking #quitsmoking

Suneela Garg Dr. Paramita Sengupta Rakesh Gupta Dr Pawan Gupta Dr REENA R KUMAR Shruti Agrawal Rishabh Agrawal Dr. Siddhi Hathiwala Dr Neha Agrawal ICanCaRe – Innovative Cancer Care and Rehabilitation Dr Shikha Jindal Consultant Pulmonologist